UP!
Puma Biotechnology is a publicly-traded pharmaceutical company (NASDAQGS: PBYI) headquartered in Los Angeles, CA. Puma in-licenses intermediate-stage drug candidates for further development. The company was founded in 2010. The current CEO is Alan Auerbach.
Currently Puma licenses three drug candidates from Pfizer: PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is an irreversible tyrosine kinase inhibitor blocking EGFR, HER1, HER2, and HER4. A new drug application was filed with the FDA for oral neratinib in July 2016.
As of December 31, 2015, they had 156 full-time employees.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-02 | Future report Set alerts | |
| Q2 2022 | 2022-08-04 | 0.00 | 0.00 |
| Q1 2022 | 2022-05-05 | -0.08 | -0.08 |
| Q4 2021 | 2022-03-03 | 0.10 | 0.10 |
| Q3 2021 | 2021-11-04 | -1.09 | -1.09 |
| Q2 2021 | 2021-08-05 | 0.00 | 0.00 |
| Q1 2021 | 2021-05-06 | 0.00 | 0.00 |
| Q4 2020 | 2021-02-25 | -0.38 | -0.38 |
| Q3 2020 | 2020-11-05 | -0.79 | 0.00 |
| Q2 2020 | 2020-08-06 | 0.08 | 0.08 |
| 2016-07-12 | Reiterated Rating | Credit Suisse Group AG | Buy | |
| 2016-05-07 | Reiterated Rating | Cowen and Company | Market Perform | |
| 2016-03-29 | Downgrade | RBC Capital | Outperform to Sector Perform | $103.00 to $36.00 |
| 2016-03-29 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $89.00 to $105.00 |
| 2016-03-29 | Reiterated Rating | Credit Suisse | Outperform | $69.00 to $50.00 |
| 2016-03-29 | Lower Price Target | Citigroup Inc. | Buy | $90.00 to $88.00 |
| 2016-03-29 | Downgrade | Royal Bank Of Canada | Outperform to Sector Perform | $103.00 to $36.00 |
| 2016-03-29 | Reiterated Rating | Credit Suisse Group AG | Outperform | $69.00 to $50.00 |
| 2016-03-28 | Reiterated Rating | Cowen and Company | Hold | |
| 2016-03-28 | Reiterated Rating | JPMorgan Chase & Co. | Buy | $105.00 to $89.00 |
| 2016-03-01 | Lower Price Target | JPMorgan Chase & Co. | Overweight | $122.00 to $105.00 |
| 2016-02-29 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $122.00 to $105.00 |
| 2016-02-19 | Lower Price Target | Citigroup Inc. | $107.00 to $90.00 | |
| 2016-02-11 | Initiated Coverage | Credit Suisse | Outperform | $69.00 |
| 2016-01-20 | Initiated Coverage | Credit Suisse | Outperform | $69.00 |
| 2016-01-05 | Upgrade | Berenberg Bank | Hold to Buy | |
| 2015-12-29 | Reiterated Rating | RBC Capital | Buy | |
| 2015-12-23 | Reiterated Rating | Cowen and Company | Market Perform | |
| 2015-12-22 | Reiterated Rating | RBC Capital | Outperform | $103.00 |
| 2015-12-14 | Lower Price Target | RBC Capital | Outperform | $285.00 to $103.00 |
| 2015-12-14 | Reiterated Rating | Stifel Nicolaus | Hold | |
| 2015-12-14 | Upgrade | Citigroup Inc. | Neutral to Buy | $67.94 to $107.00 |
| 2015-12-09 | Reiterated Rating | Citigroup Inc. | Hold | $94.00 to $85.00 |
| 2015-12-01 | Reiterated Rating | Stifel Nicolaus | Neutral | |
| 2015-09-18 | Initiated Coverage | JPMorgan Chase & Co. | Buy | |
| 2015-09-03 | Initiated Coverage | Citigroup Inc. | Neutral | |
| 2015-08-27 | Initiated Coverage | JPMorgan Chase & Co. | Overweight | $249.71 to $122.00 |
| 2015-05-27 | Reiterated Rating | RBC Capital | Outperform | $285.00 |
| 2015-05-16 | Reiterated Rating | RBC Capital | Outperform | |
| 2015-05-05 | Downgrade | Cowen and Company | Outperform to Market Perform | |
| 2015-03-12 | Downgrade | BMO Capital Markets | Outperform to Market Perform | $54.00 to $53.00 |
| 2015-03-03 | Boost Price Target | Citigroup Inc. | Buy | $263.00 to $266.00 |
| 2015-02-02 | Initiated Coverage | Bank of America | Buy | |
| 2015-02-02 | Initiated Coverage | Bank of America Corp. | Buy | |
| 2015-01-22 | Initiated Coverage | RBC Capital | Outperform | $282.00 |
| 2014-08-19 | Initiated Coverage | Stifel Nicolaus | Hold | |
| 2014-07-23 | Boost Price Target | Citigroup Inc. | Buy | $99.00 to $292.00 |
| 2014-07-23 | Boost Price Target | Leerink Swann | Outperform | $144.00 to $300.00 |
| 2014-06-24 | Reiterated Rating | Citigroup Inc. | Buy | $123.00 to $99.00 |
| 2014-04-21 | Initiated Coverage | Citigroup Inc. | Buy | $123.00 |
| 2013-12-24 | Boost Price Target | Bank of America | Buy | $118.00 to $141.00 |
| 2013-12-19 | Downgrade | Stifel Nicolaus | Buy to Hold |
| 2016-07-12 | Reiterated Rating | Credit Suisse Group AG | Buy | |
| 2016-05-07 | Reiterated Rating | Cowen and Company | Market Perform | |
| 2016-03-29 | Downgrade | RBC Capital | Outperform to Sector Perform | $103.00 to $36.00 |
| 2016-03-29 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $89.00 to $105.00 |
| 2016-03-29 | Reiterated Rating | Credit Suisse | Outperform | $69.00 to $50.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In PBYI 74 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Camber Capital Management LLC | 4.24M |
| Vanguard Group, Inc | 3.62M |
| JANUS CAPITAL MANAGEMENT LLC | 2.21M |
| BlackRock Inc. | 1.86M |
| ACADIAN ASSET MANAGEMENT LLC | 1.84M |
| RENAISSANCE TECHNOLOGIES LLC | 1.80M |
| ARMISTICE CAPITAL, LLC | 1.00M |
| BlackRock Fund Advisors | 0.84M |
| BlackRock Institutional Trust Company, N.A. | 0.78M |
| GLOBEFLEX CAPITAL L P | 0.57M |
| D. E. Shaw & Co., Inc. | 0.54M |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 0.39M |
| MORGAN STANLEY | 0.39M |
| RICE HALL JAMES & ASSOCIATES, LLC | 0.39M |
| GEODE CAPITAL MANAGEMENT, LLC | 0.37M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| AUERBACH ALAN H PRESIDENT, CEO & SECRETARY | 13.92% (4191581) | PBYI / RDUS / |
| ADAGE CAPITAL PARTNERS GP LLC | 12.27% (3696580) | ADXS / AMAG / BDBD / CALA / FPRX / HTWR / IGOI / PBYI / PSUN / PTGX / |
| Malley Thomas | 0.52% (156551) | GEVA / OVAS / PBYI / |
| EYLER CHARLES R SR. VP-FINANCE & TREASURER | 0.12% (37027) | PBYI / |
| BRYCE RICHARD PAUL SR VP, CLINICAL RESEARCH & DEV | 0.11% (34379) | PBYI / |
| CHARNAS ROBERT See Remarks | 0.10% (29461) | PBYI / |
| Lo Steven Chief Commercial Officer | 0.08% (25362) | CORT / PBYI / |
UM